Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
|
|
- Abel Elliott
- 8 years ago
- Views:
Transcription
1 Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is comprised of companies involved in the research, development, manufacturing, marketing, and selling of ethical drugs. In 2008, the global pharmaceuticals industry generated $615.1 billion in total revenues with the United States market generating $273.9 billion, or 44% of the global market. Pharmaceuticals also continue to experience positive growth, demonstrating a CAGR of 4.7% from (Appendix 1). While the industry generates healthy revenues, it is heavily concentrated within the top ten firms who accounted for more than half, $348.3 billion, of total global revenues in (Appendix 2) A trend within the pharmaceutical industry that has been developing over the past 10 years is an increase in advertising and promotional expenditures, which doubled the amount spent for R&D in the United States in As seen in Appendix 3, there are three main areas of promotional spending; however, there is one category that has seen a high growth rate in spending relative to the others since Direct to Consumer advertising (DTC) which grew 330% from $985 million in 1996 to $4,237 million in Although the DTC growth rate is relatively high compared to other promotional categories it only comprised 14% of promotional spending in Direct to Consumer Advertising DTC is one method of promotion in pharmaceuticals, but what types of advertising fall under the category of DTC? The two primary avenues are television and the Internet with the bulk of expenditures falling under television advertisements. The industry has seen a dramatic increase within this segment of promotion and many speculate that the growth was a direct result of the FDA relaxing regulations of 1 Wood, Laura. "Research and Markets: Global Top 10 Pharmaceutical Companies - Generated Total Revenues of $348.3 Billion During 2008 Reuters." Reuters.com - World News, Financial News, Breaking US & International News. Reuters, 24 July Web. 20 Oct < 2 Shaw, Amy. "Direct-to-Consumer Advertising of Pharmaceuticals, ProQuest Discovery Guides." CSA. Mar Web. 22 Oct < 3 Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < 1
2 DTC advertising in Previously, pharmaceutical companies had to list the drug s brand name and the benefits on a television commercial along with the associated risks. This led to ineffective advertisements for companies; however, when this restriction was eliminated, companies could begin to run reminder ads. These ads advertise the brand name of the drug and offer a referral website or information phone number so consumers can get more information. These types of advertisements also are exempt from risk disclosure requirements. 2 DTC advertising is attractive to pharmaceutical companies because of its ability to easily reach millions of consumers and introduce them to the product with little regulation involved. Pros & Cons of DTC The increase in DTC advertising has had large effects on the industry and pharmaceutical consumers. While many call the increased spending detrimental to the U.S. health care system, the pharmaceutical industry is quick to point out the benefits of increased DTC spending. These benefits include: increased public awareness of potential health issues and methods of treatment, better dialog with a physician through increased patient power and making the condition seem less embarrassing, and the ability to make more informed decisions through DTC advertisements and websites. 2 On the other hand, doctors and many studies seem to be split on the beneficial effects of DTC advertising. FDA surveys conducted in 1999 and 2002 found 53% of physicians believed DTC advertisements resulted in better discussions with patients and 42% of physicians believed patients were made more aware of available treatments. 4 Studies of the effect of advertising on prescribing practices have shown such advertising increases sales, helps to prevent underuse of medicines to treat chronic conditions, and at the same time, leads to some overuse of prescription drugs. 3 Some groups, such as the American College of Physicians, are more starkly against DTC advertising contending it may upset the doctor-patient relationship 5 or create a demand for prescription drugs that may not be appropriate. 6 Critics also claim physicians are often forced to take time to explain why a treatment seen on TV is not appropriate or physicians may feel pressure to prescribe drugs to accommodate the patient's request. 7 This can be especially damaging in light of revelations regarding 4 Rados, C. (2004). "Truth in Advertising: Rx Drug Ads Come of Age." FDA consumer 38(4), pp Spake, D.F. and Mathew, J. (2007). Consumer opinion and effectiveness of direct-to-consumer advertising. Journal of Consumer Marketing 24(5), pp Huh, J., Langteau, R. (2007). Presumed influence of DTC prescription drug advertising: Do experts and novices think differently? Communication Research. 34(1) pp Metzl, Jonathan M. (2007). If Direct-to-Consumer Advertisements Come to Europe: Lessons from the USA. Lancet 369(9562), pp
3 drug safety. Clinical trials required for drug approval are usually not designed to detect rare but significant adverse effects. This was seen in the case of Vioxx (rofecoxib), a drug heavily promoted to consumers that was later found to increase the risk of heart attacks. 3 In addition to potential detrimental effects of DTC advertising on doctors and patients it may also increase the monetary burden of the U.S. health care system. A Kaiser Foundation study found every $1 the pharmaceutical industry spent on DTC advertising in that year yielded an additional $4.20 in drug sales. In 2000, DTC advertising was responsible for 12% of the increase in prescription drugs sales, or an additional $2.6 billion. 8 Often times newer and more heavily advertised drugs tend to be more expensive than generic drugs or older versions of a given medication. One example of this is Avandia and Actos that treat Type 2 Diabetes and were found to be no more safe or effective than older drugs, but are much more expensive. 9 Another study found that compared with newer drugs such as Zyprexa, Seroquel, and Risperdal, older medication was found to be just as effective and up to $600 cheaper per month. 10 Along with an increase in DTC spending there has been an increase in the time it takes the FDA to issue regulatory letters asking the drug company to take specific actions in regards to DTC complaints. From the FDA letters cited advertisements for either minimizing risks, exaggerating effectiveness or both. In 2006, the Government Accountability Office criticized the FDA on behalf of U.S. Senators after the time it took to issue a regulatory letter rose from an average of two weeks from 1997 to 2001 to an average of four months from 2002 to 2005 (Appendix 4). In addition, the number of regulatory letters dropped from 142 in 1997 to 21 in One reason for this decline is the small number of staff members who review advertisements while DTC advertising continues to grow substantially. 3 This understaffing poses an issue since drug companies are not required to submit their ads before mass distribution, even though they are required to submit their final set of advertisements to the FDA. 2 The gap of time between catching errors in misleading advertisements that have been widely distributed can lead to a costly fix for pharmaceutical companies which is passed on to consumers. 8 "Impact of Direct-to-Consumer Advertising on Prescription Drug Spending - Kaiser Family Foundation." The Henry J. Kaiser Family Foundation - Health Policy, Media Resources, Public Health Education & South Africa - Kaiser Family Foundation. Web. 25 Oct < 9 CR Report. (2007). 10 Vedantam, S. (2006, Dec 1). Cost Benefits of New Schizophrenia Drugs Doubted; Older Medication, Considered Equally Effective, Can Be as Much as $600 a Month Cheaper, Study Finds. The Washington Post, pp. A.9. 3
4 Motivation for Increased DTC Spending Despite continued criticism of DTC advertising, pharmaceutical companies continue to increase the number of advertisements. If negative sentiments and complaints are surrounding DTC advertising, what are the motivating factors for drug companies to continually plaster screens with advertisements? The answer lies in increasing sales revenue, looming patent expiration dates for many large company s cash cow drugs, and the threat of generic drugs. A key motivating factor, which is linked to a company s revenue, is the approaching patent expiration dates for key drugs and the dramatic price cut that will inevitably follow due to generics entering the market. For example, a year after Zantac s patent expired prices had dropped to 15% of the pre-patent amount and to 10% the following year due to generic entry into the market. 11 Generics are a growing concern for large pharmaceutical companies who center their strategies on high revenues generated by branded, patent protected drugs. After the passing of the Drug Price Competition and Patent Term Restoration Act in 1984, generics took a larger share of the market jumping from 18.6% to 54% in Drugs losing their patent protection in 2000 resulted in an annual revenue reduction of $6.5 billion along with future cumulative losses. 11 The threat of generics and the end of patent exclusivity is a strong motivator for large pharmaceutical industries to increase promotional efforts. While companies still enjoy patent protection, they want to increase revenues from a drug by generating interest in the initial years of the drug s release. Also, by creating a brand identity with consumers through DTC advertising, companies are hoping branding will reduce losses that will occur once generics enter the market and drive down prices. This trend in the industry results in an increase in DTC advertising and promotions as a whole, despite continued criticism and increasing costs for pharmaceutical companies. Conclusion Healthcare costs continue to rise and pharmaceutical companies continue to increase their costs that ultimately get passed down to consumers. Currently, large pharmaceutical companies would lose market share and revenues if they cut back advertising. From a game theory standpoint the increases in advertising may be compared to a prisoner s dilemma. Rival companies are spending more money on a 11 Berndt, Ernst R. "The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment? -- Berndt 20 (2): Health Affairs." Health Affairs: The Policy Journal of the Health Sphere. Web. 22 Oct < 4
5 relatively stable population to gain market share. Conversely it may be beneficial for all large Pharma companies to decrease DTC advertising in order to maintain the current level of competition while reducing cost. When Congress banned cigarette advertising in 1970 earnings at the major cigarette producers were up 30% in 1971 as compared to 1970 by eliminating the advertising rivalry which did not greatly affect sales. In an industry with increasing political controversy, decreasing healthcare costs for consumers will be a priority for large pharmaceutical companies who wish to remain competitive within a changing industry. 5
6 Appendix 1: Global Pharmaceuticals Market Value: $ Billion Datamonitor, Global Pharmaceutical Industry Appendix 2: Pharmaceutical Industry s Concentration Top Ten Firms Revenue Rank Company Country Total revenues ($bn) 1 Pfizer U.S. $ Johnson & Johnson U.S. $ GlaxoSmithKline United Kingdom $ Bayer Germany $ Hoffmann-La Roche Switzerland $ Sanofi-Aventis France $ Novartis Switzerland $ AstraZeneca UK/Sweden $ Abbott Laboratories U.S. $ Merck & Co. U.S. $ Total Revenues $ Source: Top 50 Pharmaceutical Companies Charts & Lists, Med Ad News, September
7 Appendix 3: Direct-to-Consumer Advertising and Promotion to Health Professionals, Source: Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < Appendix 4: Complaints and Regulatory Letters Written Concerning DTC Advertising Source: Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < 7
Impact of Direct-to-Consumer Advertising on Prescription Drug Spending
Impact of Direct-to-Consumer Advertising on Prescription Drug Spending June 2003 The Kaiser Family Foundation is an independent, national health philanthropy dedicated to providing information and analysis
More informationPharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch
Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry
More informationPharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366
Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 1.0 Executive Summary 2.0 Situation Analysis 2.1 Market Summary 2.1.1 Market Demographics 2.1.2 Market Needs 2.1.3 Market Trends
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationReducing Waste with an Efficient Medicare Prescription Drug Benefit
Issue Brief January 2013 Reducing Waste with an Efficient Medicare Prescription Drug Benefit BY DEAN BAKER* When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that
More informationPharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story
Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology
More informationThe NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005
EMBARGOED FOR RELEASE 6 p.m. EST, June 2 Summary The NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005 An Analysis by Consumers Union and Consumer Reports Best Buy Drugs June 2005 Doctors
More informationSeries 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING
West Virginia Title 210 LEGISLATIVE RULE GOVERNOR S OFFICE OF HEALTH ENHANCEMENT AND LIFESTYLE PLANNING (GOHELP) Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING 210-1-1. General. 1.1. Scope. --
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationI ve been asked to talk about the Pharmaceutical Benefits Scheme in the context of Medicare and the broader health sector.
1 Sustaining the PBS for the future Dr Brendan Shaw, Chief Executive, Medicines Australia Speech to 2 nd Future of Medicare Conference 11 November 2010, Sydney Thank you for the opportunity to speak with
More informationData Trends Report. Encuity. Testosterone Replacement Therapy
Encuity Data Trends Report Encuity has cost-effective solutions to suit your business needs through our various syndicated services. Encuity Data Trends Report provides insight on how our collective services
More informationNew Multi-Marketing Channel Strategies
Brochure More information from http://www.researchandmarkets.com/reports/1082161/ New Multi-Marketing Channel Strategies Description: The future of Pharma marketing lies in using new marketing channels
More informationRising Health Care Costs What Factors are Driving Increases?
Rising Health Care Costs What Factors are Driving Increases? Rising health care costs and access to affordable coverage are prominent issues for Washington employers, health care providers, purchasers,
More informationMonetary and Political Effects of Product Liability Lawsuits in. the Pharmaceutical Industry. Constructed By: Spenser Hanson.
Monetary and Political Effects of Product Liability Lawsuits in the Pharmaceutical Industry Constructed By: Spenser Hanson Joe Wadle October 24 th, 2009 G400: Professor Andreas Hauskrecht Introduction
More informationSetting the Record Straight about Medicare
Fact Sheet Setting the Record Straight about Medicare Keith D. Lind, JD, MS As the nation considers the future of Medicare, it is important to separate the facts from misconceptions about Medicare coverage,
More informationUnderstanding Prescription Assistance Programs (PAPs)
Understanding Prescription Assistance Programs (PAPs) The use of prescription medicines has become an increasingly important part of quality medical care. Two out of every three visits to the doctor end
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationPRESCRIPTION MEDICINES: COSTS IN CONTEXT
PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise
More informationThe Factors Fueling Rising Health Care Costs 2008
The Factors Fueling Rising Health Care Costs 2008 Prepared for America s Health Insurance Plans, December 2008 2008 America s Health Insurance Plans Table of Contents Executive Summary.............................................................2
More informationPharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells
Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors
More informationPharma Promotional Spending in 2013
May 2014 Vol. 13, No. 5 Pharma Marketing Network www.pharmamarketingnews.com Pharma Promotional Spending in 2013 Professional Detailing, edetailing, DTC Advertising, Professional Meetings, Journal Advertising
More informationGreat Expectations: Why Pharma Companies Can t Ignore Patient Services
Accenture Life Sciences Rethink Reshape Restructure... for better patient outcomes Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Research Note: Key findings from a survey
More informationDirect-to-Consumer Advertising (DTC) of Pharmaceuticals by Amy Shaw
Introduction Discovery Guides Direct-to-Consumer Advertising (DTC) of Pharmaceuticals by Amy Shaw A popular sleep advertisement shows an unshaven insomniac at a kitchen table with Abe Lincoln and a talking
More informationFact Sheet. Prescription Data Mining
November 19, 2008 Fact Sheet Prescription Data Mining The Prescription Project promotes evidence-based prescribing and works to eliminate conflicts of interest in medicine due to pharmaceutical marketing
More informationU.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA
Page 35 U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA Guy W. Giorno, Lynne Golding, Vincent Routhier, and Philippe David Fasken Martineau DuMoulin LLP INTRODUCTION Legislation currently before
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationAltering Medical Relationships by Pharmaceutical Advertising to the Public
Altering Medical Relationships by Pharmaceutical Advertising to the Public Nowhere within this discussion do I wish to argue that a patient should have information denied from them, however clearly advertising
More informationTABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition
TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition SUMMARY OF SALIENT POINTS Importance and Competitiveness of the Ethical Pharmaceutical Industry Government
More informationEighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry
Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry July 2014 FOR FURTHER INFORMATION, PLEASE CONTACT: John Mangano comscore, Inc. +1 (703) 438-2358 jmangano@comscore.com
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationSpecialty Drug Hyperinflation:
Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty
More informationThe Impact of Prescription Drug Prices on Seniors
The Impact of Prescription Drug Prices on Seniors Over the years medicine has changed, particularly with respect to prescription drugs: more drugs are available, they are more frequently prescribed, and
More informationBlockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global
Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com
More informationIMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS
Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF
More informationBARACK OBAMA S PLAN FOR A HEALTHY AMERICA:
BARACK OBAMA S PLAN FOR A HEALTHY AMERICA: Lowering health care costs and ensuring affordable, high-quality health care for all The U.S. spends $2 trillion on health care every year, and offers the best
More informationRx-360 An International Pharmaceutical Supply Chain Consortium
Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)
More informationDirect-to-Consumer Advertising of Prescription Drugs: Exposure and Response
Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response November 2010 Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response Report Prepared by Helen Brown COPYRIGHT
More informationMedicare part d, which offers
Trends The Effects Of The Coverage Gap On Drug Spending: A Closer Look At Medicare Part D Beneficiaries who entered the doughnut hole decreased their monthly prescriptions by about percent per month. by
More informationThe facts about rising health care costs Underlying medical costs drive growth
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions The facts about rising health care costs Underlying medical costs drive growth October 2012 00.03.966.1-L11 A
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationHealth Policy 201 drugs. Ellen Andrews, PhD Fall 2011
Health Policy 201 drugs Ellen Andrews, PhD Fall 2011 benefits Since the mid-1990s, when researchers developed a new wave of medicines to treat HIV/AIDS, the U.S. death rate from AIDS dropped about 70 percent.
More informationMultiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
More informationAn Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements
An Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements And Implications for Current Food and Drug Administration Oversight of Direct to Consumer Advertisement Regulations
More informationGlobal Policy on Interactions with Healthcare Professionals
Global Policy on Interactions with Healthcare Professionals Global Policy on Interactions with Healthcare Professionals Pfizer is committed to collaborating with physicians and other healthcare professionals,
More informationIncome Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop
Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements
More informationInvestor science conference call: American College of Cardiology 2015
Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to
More informationWhen investigative sites are struggling with subject recruitment, and it
PEER REVIEWED When investigative sites are struggling with subject recruitment, invariably, someone will propose paying noninvestigator physicians for referrals, while others will be adamant in their opposition
More informationNAHU. The Role of the Health Insurance Professional in Educating America. by Scott Leavitt. NAHU President
NAHU The Role of the Health Insurance Professional in Educating America by Scott Leavitt NAHU President Introduction To help licensed agents, brokers & consultants understand that they have a serious responsibility
More informationPharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring
Pharmaceutical Policy in : Role of Health Insurance in Pricing, Reimbursement and Monitoring Soonman KWON* and Sukyeong KIM** *Dean, School of Public Health Seoul National University ** Director, Research
More informationBig Data and Healthcare Information. Ed Reiner Quintiles Transnational
Big Data and Healthcare Information Ed Reiner Quintiles Transnational About Me 30 years in the information sector McGraw-Hill Information Division Elsevier Science (Cardiosource, ScienceDirect) Medical
More informationThe Industry. Johnson and Johnson is involved in the health care industry. through three distinct business segments: consumer, medical, and
1 Johnson and Johnson Analysis Andrew West and The Industry Johnson and Johnson is involved in the health care industry through three distinct business segments: consumer, medical,
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationThe Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals
The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationTHE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS
THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS I. Mission: Seton Hall Law School, Sciences Po, and ETHICS - the International Society of Healthcare Ethics and Compliance Professionals,
More informationHIKMA PHARMACEUTICALS PLC. J.P. Morgan 29 th Annual Healthcare Conference 2011. San Francisco, CA
HIKMA PHARMACEUTICALS PLC J.P. Morgan 29 th Annual Healthcare Conference 2011 San Francisco, CA This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides
More informationWhistleblower Cases an Overview
Whistleblower Cases an Overview by John P. Leader, Esq. 1 1 John is a former Assistant United States Attorney, where he practiced for nine (9) years in the Criminal Division of the Arizona Office. Page
More informationMedicare Advantage and Part D Fraud, Waste, and Abuse Training. October 2010
Medicare Advantage and Part D Fraud, Waste, and Abuse Training October 2010 Introduction 2008: United States spent $2.3 trillion on health care. Federal fiscal year 2010: Medicare expected to cover an
More informationGroup insurance. Generic drugs. Their positive effect on your wallet
Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them
More informationInforming the Uninformed: How Drug Advertising Affects Check-Up Visits
Informing the Uninformed: How Drug Advertising Affects Check-Up Visits Daniel Hosken Brett Wendling Federal Trade Commission* November 2009 *The opinions expressed here are those of the authors and not
More informationBattle for the market: Branded drug companies secret weapons generic drug makers must know
Battle for the market: Branded drug companies secret weapons generic drug makers must know Received (in revised form): 28 th March, 2005 Jon Hess is a senior analyst and consulting project leader with
More informationCost Trends & Care Management 2002 Market Survey Highlights. The Impact of Disease Management Intervention on Healthcare Costs
Med Vantage, Inc Cost Trends & Care Management 2002 Market Survey Highlights The Impact of Disease Management Intervention on Healthcare Costs December 2 13, 2002 Geof Baker, President Med-Vantage, Inc.
More informationLITIGATION FUNDING FREQUENTLY ASKED QUESTIONS
LITIGATION FUNDING FREQUENTLY ASKED QUESTIONS 1. WHAT IS THE LITIGATION FUNDING PROGRAM? In simple terms, it is a mutually agreed upon contract between a legal marketing firm and another party, a Funder.
More informationOpportunities in the China Healthcare Sector. December 2008
Opportunities in the China Healthcare Sector December 28 Opportunities in the China Healthcare Sector Executive Summary China s healthcare sector is rapidly developing Total Health expenditure in China
More informationISSUE BRIEF. Pharmaceutical Discounts for Medicare Beneficiaries Can Save Seniors Money. September 2002
Pharmaceutical Discounts for Medicare Beneficiaries Can Save Seniors Money Prescription Drug Gap in Medicare The majority of people over 65 in the United States have coverage for medical care through the
More informationPaul Appelbaum, Julio Arboleda-Flórez, Afzal Javed, Constantin Soldatos, Sam Tyano. WPA Standing Committee on Ethics
for relationships of psychiatrists, health care organizations working in the psychiatric field and psychiatric associations with the pharmaceutical industry Paul Appelbaum, Julio Arboleda-Flórez, Afzal
More informationBreast Cancer Drug Discoveries: What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to
More informationHow To Use Social Media For A Pharmaceutical Company
Leveraging Social Media for Pharmaceutical Companies Realized by Synthesio Summary Introduction.2 Social media and the new health paradigm.3 Millions of online consumer conversations to explore.4 Detecting
More informationStephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015
Life Sciences Industry in Canada Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences in Canada Canadian life sciences
More informationImproved Medicare for All
Improved Medicare for All Quality, Guaranteed National Health Insurance by HEALTHCARE-NOW! Single-Payer Healthcare or Improved Medicare for All! The United States is the only country in the developed world
More informationGeneric substitution of prescription drugs
Generic substitution of prescription drugs Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (2)2003 Author(s): Ilmo Keskimäki and Lauri Vuorenkoski
More informationWhen treating a disease is bad business: orphan and neglected diseases
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
More informationImproved Medicare for All
Take Action: Get Involved! The most important action you can take is to sign up for Healthcare-NOW! s email list, so you can stay connected with the movement and get updates on organizing efforts near
More informationGCC Pharmaceutical Industry
GCC Pharmaceutical Industry First coordination meeting for the pharmaceutical industry in the GCC and Yemen Dr. Aasim Qureshi 11 April 2011 Global Pharmaceuticals Industry The pharmaceutical industry is
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationResponse to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers
Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick
More informationThe Unintended Effects of
The Unintended Effects of Healthcare Reform TOM SUROVY, PRINCIPLE COMPLIANCE ATTORNEY CONTENTS CHILD-ONLY POLICIES... 3 PRESCRIPTIONS FOR NONPRESCRIPTION OVER-THE-COUNTER DRUGS... 4 COMMISSIONS FOR INSURANCE
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationDiscount Healthcare Programs: A Consumer s Guide to Choosing the Best Program
Discount Healthcare Programs: A Consumer s Guide to Choosing the Best Program About the Consumer Health Alliance The Consumer Health Alliance (CHA) is the national trade association of the discount healthcare
More informationHealth Care Job Information Sheet #20. Clinical Research
Health Care Job Information Sheet #20 Clinical Research A. Background B. Occupations 1) Clinical Research Associate (Study Monitor) 2) Clinical Research Coordinator 3) Other positions in the field C. Labour
More informationStewart B. Harris MD, MPH, FCFP, FACPM. 2 nd Annual Congress of the Global Diabetes Alliance (GDA) October 26-29, 2010 Cairo, Egypt
SUMMIT SESSION: The challenges and applications of diabetes registries and electronic medical records (EMR's) in improving clinical care for patients with diabetes; a global perspective 2 nd Annual Congress
More informationCourse Description: 1) Health insurance
MEC 400G / 500I: Economic Issues and the Management of Healthcare Professor Gautam Gowrisankaran John M. Olin School of Business Washington University in St. Louis Fall 2005 Introduction: The purpose of
More informationSTATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry
Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators
More informationPrinciples on Health Care Reform
American Heart Association Principles on Health Care Reform The American Heart Association has a longstanding commitment to approaching health care reform from the patient s perspective. This focus including
More informationPatient Services Pharma s Best Kept Secret
Accenture Life Sciences Rethink Reshape Restructure...for better patient outcomes Patient Services Pharma s Best Kept Secret Accenture Research Note: Key findings from a survey of 10,000 patients around
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More informationMedicine and the Pharmaceutical Industry - How Did We Get Here? Where Are We Going?
Medicine and the Pharmaceutical Industry - How Did We Get Here? Where Are We Going? Deborah Way, MD, CMD LIFE University of Pennsylvania School of Nursing Pamela Fenstemacher, MD, CMD LIFE at Home Faculty
More informationPfizer Helpful Answers Pfizer s Family of Patient Assistance Programs. Helping the Uninsured and Underinsured Get Access to the Medicines They Need
Pfizer Helpful Answers Pfizer s Family of Patient Assistance Programs New Haven, CT Helping the Uninsured and Underinsured Get Access to the Medicines They Need Pfizer Helpful Answers is a joint program
More informationGAO PRESCRIPTION DRUGS. Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising. Report to Congressional Requesters
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 PRESCRIPTION DRUGS Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising GAO-07-54
More informationPotential for Apps in Pharmaceutical Development. Steve Hutson Co-founder Virtual PV
Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical
More informationAND STILL GET HIGH QUALITY CARE?
HOW CAN WE REDUCE OUR HEALTH CARE SPENDING AND STILL GET HIGH QUALITY CARE? A Choicework discussion guide from Public Agenda, developed through a collaborative research project with the Kettering Foundation
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationCanadian Doctors for Medicare Neat, Plausible, and Wrong: The Myth of Health Care Unsustainability February 2011
Canadian Doctors for Medicare Neat,Plausible,andWrong: TheMythofHealthCareUnsustainability February2011 340 Harbord Street, Toronto, Ontario Phone: 1-877-276-4128 / 416-351-3300 E-Mail: info@canadiandoctorsformedicare.ca
More informationFrom academic journals to the
Health Tracking Trends Comparing And Private Insurers: Growth Rates In Spending Over Three Decades can be counted on to control per enrollee spending growth over time, more than private insurers can. by
More informationArticle from: Health Section News. April 2003 Issue No. 45
Article from: Health Section News April 2003 Issue No. 45 Issue No.45 April 2003 Health Section News For Professional Recognition of the Health Actuary Genetic Testing, Medical Progress and the Health
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationPharma s Sharp Right Turn on R&D Creating an IT Platform to Fuel Future Growth
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Pharma s Sharp Right Turn on R&D Creating an IT Platform to Fuel Future Growth Leading pharmaceutical companies are evaluating
More informationI SSUE B RIEF. Providing Prescription Drugs to Seniors: A Patchwork of Coverage. Introduction
A Spring 2001 I SSUE B RIEF A MERICAN A CADEMY of A CTUARIES Providing Prescription Drugs to Seniors: A Patchwork of Coverage Prescription drug coverage for seniors is a key issue being debated at both
More information